Nestlé breaks into diagnostics, acquiring Prometheus for rumoured $1bn
This article was originally published in Clinica
Food giant Nestlé is expanding its presence in the healthcare market by agreeing to buy US gastrointestinal and cancer diagnostics specialist Prometheus Laboratories. Although the Swiss group has not disclosed financial terms of the deal, a figure of around $1bn for the merger consideration has been touted by analysts and the press.
You may also be interested in...
Nestlé Health Science has invested $23m in a joint venture it is setting up with French microbiome company Enterome. Microbiome Diagnostics Partners (MDP) will be focused on developing microbiome-based diagnostics for the assessment and management of irritable bowel disorder and liver diseases.
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.